Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 10/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.35 |
| ▸ | ME2 | P23368 | 2/20 | 0.33 |
| ▸ | ME1 | P48163 | 2/20 | 0.33 |
| ▸ | ME3 | Q16798 | 2/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27910701 | 0.81 | FFAR1 (0.38) | FFAR1 | |
| SCHEMBL13680812 | 0.77 | ESR1 (0.42) | ESR1ESR2FFAR1DEGS1 | |
| SCHEMBL27893674 | 0.76 | SLC2A1 (0.47) | — | |
| SCHEMBL851581 | 0.75 | MIF (0.44) | ESR1ESR2FFAR1DEGS1 | |
| SCHEMBL28018963 | 0.72 | ESR1 (0.39) | ESR1ESR2DEGS1 | |
| SCHEMBL2080801 | 0.72 | CYP4F2 (0.47) | ESR1ESR2 | |
| SCHEMBL19555364 | 0.72 | ESR1 (0.44) | ESR1ESR2DEGS1 | |
| SCHEMBL2429377 | 0.71 | ESR1 (0.47) | ESR1ESR2FFAR1DEGS1 | |
| SCHEMBL19079047 | 0.71 | ESR1 (0.39) | ESR1ESR2FFAR1DEGS1ME2 | |
| SCHEMBL4178273 | 0.70 | CA2 (0.50) | ESR1ESR2FFAR1DEGS1ME2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | FIVE ELEVEN PHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | KLK3, FOLH1, UTS2R | ESR1 1149/4885ESR2 1747/4885FFAR1 742/4885 |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | KLK3, FOLH1, UTS2R | ESR1 1149/4885ESR2 1747/4885FFAR1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.